Your browser doesn't support javascript.
loading
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.
Petrone, Linda; Petruccioli, Elisa; Alonzi, Tonino; Vanini, Valentina; Cuzzi, Gilda; Najafi Fard, Saeid; Castilletti, Concetta; Palmieri, Fabrizio; Gualano, Gina; Vittozzi, Pietro; Nicastri, Emanuele; Lepore, Luciana; Grifoni, Alba; Antinori, Andrea; Vergori, Alessandra; Ippolito, Giuseppe; Cantini, Fabrizio; Goletti, Delia.
Afiliação
  • Petrone L; Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Petruccioli E; Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Alonzi T; Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Vanini V; Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Cuzzi G; Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Najafi Fard S; Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Castilletti C; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Palmieri F; Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Gualano G; Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Vittozzi P; Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Nicastri E; Clinical Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Lepore L; Clinical Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Grifoni A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Antinori A; HIV/AIDS Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Vergori A; HIV/AIDS Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Ippolito G; Scientific Direction, National Institute for Infectious Disease "Lazzaro Spallanzani"-IRCCS, Rome, Italy.
  • Cantini F; Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy.
  • Goletti D; Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy. Electronic address: delia.goletti@inmi.it.
J Infect ; 82(4): 58-66, 2021 04.
Article em En | MEDLINE | ID: mdl-33639176
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article